Tag - Dusa

Right now, about 58 million Americans suffer from the most common form of skin pre-cancer - Actinic Kerotosis (AK). I say pre-cancer because with the right treatment, this relatively common skin condition can be prevented.

But, if not treated properly there is a possibility that the condition could get a lot worse - it could even become life threatening.

It is not my place to give you advice on which medical treatments you should choose for particular illnesses and conditions - I am not a doctor. However, I do specialize in finding opportunities to invest in small cap growth companies that have the opportunity to make significant returns.

Dermatology company DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) reported a net loss for the third quarter that was narrower than analysts had expected, propping up shares in pre-market trading.

For the three months ended Sept. 30, the Wilmington, Mass.-based company recorded a net loss of $1.4 million, or $0.07 per share, narrower than the loss of $0.16 per share three analysts polled by Thomson were on average anticipating. For the third quarter of 2006, the small cap incurred a net loss of $2.9 million, or $0.15 per share

Revenues for the three months were $5.78 million, compared with revenues of $6.1 million for the same period in 2006. Three analysts had on average forecasted revenues of $5.9 million for the quarter.

Total product revenues for the quarter were $5.8 million, compared with $6.1 million for the same period in 2006. PDT revenues totaled $3.5 million, compared with revenues of $3.2 million for the same period in 2006. Increases in PDT revenues were driven primarily by a 17% increase in U.S. Levulan Kerastick revenue.

Non-PDT revenues totaled $2.3 million, compared with $2.8 million for the same period in 2006. DUSA said non-PDT revenues were primarily driven by the sales of Nicomide, which were adversely impacted by the presence of the River's Edge product, which re-entered the market in March.

Shares of DUSA Pharmaceuticals (DUSA) jumped 24.38%, or $0.49, to $2.50 ahead of the opening. Shares of DUSA Pharmaceuticals have been trading in the range of $1.63 to $5.89 for the past 52 weeks.

DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) has been granted an orphan drug designation by the U.S. Food and Drug Administration for its drug Levulan, which treats esophageal dysplasia, the Wilmington, Mass.-based dermatology company said this morning.  Esophageal dysplasia is a leading cause of esophageal cancer.  Once a company receives approval from the FDA to market its orphan-designated product, it is entitled to seven years of marketing exclusivity.  Nevertheless, shares are up $0.15, or 5%, to $2.77.